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Multiple osteochondromas (MO), the most common type of benign bone tumor, is an
autosomal dominant skeletal disorder characterized by multiple cartilage-capped bony
protuberances. In most cases, EXT1 and EXT2, which encode glycosyltransferases
involved in the biosynthesis of heparan sulfate, are the genes responsible. Here we
describe the clinical, phenotypic and genetic characterization of MO in 22 unrelated
Chinese families involving a total of 60 patients. Variant detection was performed by
means of a battery of different techniques including Sanger sequencing and whole-
exome sequencing (WES). The pathogenicity of the missense and splicing variants
was explored by means of in silico prediction algorithms. Sixteen unique pathogenic
variants, including 10 in the EXT1 gene and 6 in the EXT2 gene, were identified in 18
(82%) of the 22 families. Fourteen (88%) of the 16 variants were predicted to give rise
to truncated proteins whereas the remaining two were missense. Seven variants were
newly described here, further expanding the spectrum of MO-causing variants in the
EXT1 and EXT2 genes. More importantly, the identification of causative variants allowed
us to provide genetic counseling to 8 MO patients in terms either of preimplantation
genetic testing (PGT) or prenatal diagnosis, thereby preventing the reoccurrence of
MO in the corresponding families. This study is the first to report the successful
implementation of PGT in MO families and describes the largest number of subjects
undergoing prenatal diagnosis to date.
Keywords: EXT1 gene, EXT2 gene, multiple osteochondromas, pathogenic variant, preimplantation genetic
testing, prenatal diagnosis
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INTRODUCTION
Multiple osteochondromas (MO) (OMIM 133700-133701),
also known as hereditary multiple exostoses (HME) or
osteocartilaginous exostosis, is an autosomal dominant skeletal
disorder characterized by the formation of benign cartilage-
capped bony protuberances, typically arising on the metaphyses
of long tubular bones (Bovee, 2008). The malformation of legs,
forearms and hands is a frequent manifestation (Matsubara
et al., 2006). The prevalence of MO is estimated to be 1/50,000
(Wicklund et al., 1995) and would appear to be higher in
males (male-to-female ratio, 1.5:1) (D’Arienzo et al., 2019),
making it one of the most frequent causes of skeletal dysplasia.
MO is characterized by significant inter- and intra-familial
phenotypic heterogeneity, including variation in the number
and size of osteochondromas, the number and location of
the bones involved, and the degree of the deformities arising
(Peterson, 1989). Osteochondromas are rarely present at birth,
but rather appear and grow during the first decade of life,
finally ceasing to grow when the growth plates close at the
end of puberty. Approximately 62% of MO patients have
a positive family history, with nearly complete penetrance
(Schmale et al., 1994).
Benign as the osteochondromas are, they can lead to several
complications. By exerting pressure on neighboring tissues,
osteochondromas cause pain, nerve compression, and other
conditions (Pedrini et al., 2005). Skeletal malformations are also
observed in MO patients with limb length inequalities, restricted
range of joint motion and short stature (Porter et al., 2004).
At present there is no etiological treatment, so surgery may be
the only way to correct the severe deformities. Although MO
does not in itself affect life expectancy, malignant transformation
to a chondrosarcoma occurs in 1–5% of cases (Peterson, 1989;
Pedrini et al., 2011).
MO is genetically heterogeneous. To date, three loci for
MO have been mapped and two genes, EXT1 (Entrez gene
ID: 2131, alias: Exostosin1) and EXT2 (Entrez gene ID: 2132,
alias: Exostosin2), have been cloned (Ahn et al., 1995; Stickens
et al., 1996). EXT1 consists of 11 exons and spans ∼312 kb
at 8q24 (Ludecke et al., 1997), while EXT2 comprises 16
exons and is located at 11p11.2, spanning ∼150 kb (Clines
et al., 1997). The genes belong to the EXT multigene family,
are ubiquitously expressed and act as tumor suppressors. All
members of this family encode proteins that are involved in the
adhesion and/or polymerization of heparin sulfate (HS) chains
at HS proteoglycans (HSPG’s) (Lind et al., 1998; McCormick
et al., 1998; Busse et al., 2007). EXT1 and EXT2 function
as glycosyltransferases that participate in the biosynthesis of
heparin sulfate (HS) to modify proteoglycans. HS proteoglycans,
synthesized by chondrocytes and secreted to the extracellular
matrix of the growth plate, play critical roles in growth plate
signaling and remodeling.
To date, hundreds of EXT1 and EXT2 variants have been
registered in the Human Gene Mutation Database (HGMD)1
1http://www.hgmd.cf.ac.uk/ac/search.html
(Stenson et al., 2020) as well as in the EXT12 and EXT23 locus-
specific mutation databases. Most of the known pathogenic
variants cause truncation of the encoded proteins, e.g., frameshift,
non-sense, and splice site mutations; pathogenic missense
variants are uncommon (Santos et al., 2018; Fusco et al.,
2019). The application, more recently, of structural variant-
detection techniques such as multiplex ligation-dependent probe
amplification (MLPA) and microarray analysis has served to
increase the variant detection rate from 70 to 85% (Li et al.,
2018; Fusco et al., 2019). In the present study, we report the
genetic findings from 22 Chinese MO families together with the
successful use of this information to potentiate preimplantation
genetic testing (PGT) and prenatal diagnosis in 8 MO families.
MATERIALS AND METHODS
Ethics Statement
This study was approved by the Ethics Committee of Sun
Yat-sen University. All participants (or parents/guardians when
the participants were under the age of 18) gave their
informed consent.
Subjects
Sixty MO patients (41 male) from 22 unrelated Chinese families
participated in this study. All probands were referred to the First
Affiliated Hospital of Sun Yat-sen University from January 2011
to September 2018. A diagnosis of MO was made on clinical,
radiographic and laboratory findings, in particular the existence
of at least two exostoses at the juxta-epiphysial regions of the long
bones (Legeai-Mallet et al., 1997).
Sanger Sequencing
Genomic DNA was extracted from peripheral blood using the
QiAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany).
Primers were designed by Primer Premier 3.04 to amplify
each exon and intron/exon junction of the EXT1 and EXT2
genes (primer sequences and PCR conditions are available
upon request). The resulting PCR products were sequenced on
the ABI 3730XL DNA Genetic Analyzer (Applied Biosystems,
Foster City, CA), using the ABI BigDye Terminator v3.1 Cycle
Sequencing Kit.
Whole-Exome Sequencing
Genomic DNA was fragmented randomly and then purified
by means of the magnetic particle method. Sequences were
captured by Agilent SureSelect version 4 (Agilent Technologies,
Santa Clara, CA) according to the manufacturer’s protocols. The
DNA libraries, after enrichment and purification, were sequenced
on the NextSeq500 sequencer according to the manufacturer’s
instructions (Illumina, San Diego). The sequencing reads were
aligned to GRCh37.p10 using Burrows-Wheeler Aligner software
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base quality recalibration of the Burrows-Wheeler aligned reads
were then performed using the GATK IndelRealigner5 and
GATK BaseRecalibrator6, respectively. SNVs and small indels
were identified by the GATK UnifiedGenotyper7. Variants were
annotated using the Consensus Coding Sequences Database at
the National Centre for Biotechnology Information8.
Multiplex Ligation-Dependent Probe
Amplification, Fluorescence in situ
Hybridization and Whole Genome
Sequencing
These methods have been described in detail elsewhere (Su et al.,
2015; Wang et al., 2015).
Reference Sequences and Variant
Nomenclature
NM_000127.2 and NM_207122.1 were used as EXT1 and EXT2
mRNA reference sequences, respectively. Variant nomenclature
followed HGVS recommendations (den Dunnen et al., 2016).
Variants were checked against the Human Gene Mutation
Database (HGMD)9 as well as the EXT1 or EXT2 locus-
specific mutation database to identify previously described
lesions (as of 12 Sep 2020). For those that were newly
described here, their nomenclature was verified via VarSome10
(Kopanos et al., 2019).
Pathogenicity Predictions
The PP3 rule established by VarSome (Kopanos et al., 2019)
was adopted to predict the pathogenicity of EXT1 missense
variants as previous described (Gueguen et al., 2020). The
PP3 verdict was based upon the combined consideration
of predictions from a dozen in silico programs including
BayesDel_addAF, DEOGEN2, FATHMM-MKL, M-CAP, MVP,
MutationAssessor, MutationTaster, PrimateAI, REVEL and
SIFT. In silico splicing prediction was performed by means of
Alamut R©Visual v.2.11 rev. 011 (Interactive Biosoftware, Rouen,
France) and SpliceAI. Alamut includes five prediction algorithms,
namely SpliceSiteFinder-like, MaxEntScan, NNSPLICE,
GeneSplicer, and Human Splicing Finder. SpliceAI is a recently
developed deep residual neural network for splicing prediction
(Jaganathan et al., 2019).
Structural Modeling of EXT1
Structural modeling of human EXT1 was carried out using the












Discovery Studio 3.5 (Accelrys, San Diego, California). The
refined model was validated by the VERIFY-3D program in
Discovery Studio 3.5. The model figure was prepared using
PyMol (DeLano, 2002).
Preimplantation Genetic Testing (PGT)
The oocyte retrieval, embryo culture, and biopsy methods were
used as previously described (Liu et al., 2020). The biopsied
trophectoderm cells transferred to phosphate buffer saline were
subjected to whole-genome amplification (WGA) using the
Multiple Displacement Amplification approach (REPLI-g Single
Cell Kit, QIAGEN Inc.).
Three couples were offered counseling and information
on different PGT platforms. SNP microarrays were used for
Family 4-II-3 and Family 13-II-5. The peripheral blood DNA
of parents and reference samples (abortion with EXT1 mutation
or affected parent), together with the embryo samples from
the WGA, were analyzed using HumanKaryomap-12 BeadChips
(Illumina, San Diego, CA, United States) according to the
manufacturer’s instructions. The scanning results were analyzed
using BlueFuse Multi V4.5 software provided by Illumina.
The haplotypes in each pedigree was performed in the EXT1
regions as well as 2 Mb upstream and downstream of this
gene. At the same time, the B allele and Log R Ratio
data were obtained from the scanning results produced by
Illumina Genome studio 2.0 software for aneuploidy screening.
Next-generation sequencing (NGS) platforms were used for
the two PGT cycle in Family 5-II-3. The EXT1 region was
selected as the target region. A total of 31 high density
and closely linked SNPs mapping within 2 Mb upstream
of the gene and 33 linked SNPs mapping within 2 Mb
downstream of the gene, were selected. Following mixing with
corresponding PCR amplicons of the SNPs and mutations,
the WGA products were used for the library construction
of NGS. DNA purification, cDNA library construction and
sequencing using the Illumina MiSeqDX were performed
sequentially. Haplotypes were established by selection of several
informative SNPs. The mutations in all samples were subjected
to Sanger sequencing for verification. For PGT-A (PTG for
aneuploidies), the VeriSeq PGS-MiSeq kit (Illumina) was used
to prepare the NGS libraries. The MiSeq Reagent Kit v3-
PGS (Illumina, San Diego, CA, United States) was used
to perform dual-index 36-bp read sequencing according to
the VeriSeq PGS recipe. MiSeq Reporter software (Illumina,
San Diego, CA, United States) was used to make on-board
secondary data analysis (Fiorentino et al., 2014). Detection
and classification of aneuploidies was determined by copy
number variation (CNV) values. The frozen-thawed embryos
without EXT1 mutations were transferred as previously described
(Liu et al., 2020).
RESULTS
Clinical Features of the Patients
The family trees of the 22 families are presented in Figure 1.
Four families have been previously described [i.e., family
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FIGURE 1 | Pedigrees of the 22 Chinese families with multiple osteochondromas. Filled squares or circles denote patients. Open symbols denote clinically
unaffected family members. Circles with question marks denote members with questionable clinical features and no imaging tests. Arrows indicate
probands. + identifies those subjects subjected to genetic analysis. In Families 1–18, all patients subjected to genetic analysis harbored the variant of interest
whereas the clinically healthy subjects did not. In Families 19–22, no pathogenic variants were found in any of the individuals subjected to genetic analysis. Those
individuals who were born healthy through the preimplantation genetic testing are denoted by # whereas those who directly received prenatal diagnosis as a fetus
are denoted by *. Subjects analyzed by WES were indicated by squares.
11 in Su et al. (2015) and families 16–18 in Wang et al.
(2015)] whereas the remaining 18 families are reported
for the first time. Detailed information pertaining to the
clinical features exhibited was available for 36 patients, and
is summarized in Table 1. Specifically, in the informative
patients, osteochondroma/exostoses generally occurred in the
long bones of the upper and lower limbs; chest bones (rib,
sternum, scapulae, claviculae) [27.8% (10/36)] and hip (ilium,
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pubis, ischium) [11.1% (4/36)] were the next most commonly
affected sites whereas vertebral osteochondroma/exostoses were
found only in a single patient (i.e., Family 15-III-1). About
25.0% (9/36) of patients had a deformity of the limbs
and joints whilst only three patients had pain in one or
more affected locations. A total of 12 patients (33.3%)
underwent surgery to correct the deformity. Finally, malignant
transformation to chondrosarcoma occurred in two patients
(i.e., Family 10-II-1 and Family 14-II-1) whilst the absence
of a uterus was revealed in one patient (i.e., Family 7-
III-1). Some aspects of the clinical features are also shown
in Figure 2.
TABLE 1 | Clinical characteristics of the multiple osteochondromas patients in 22 families.
Patient Sex Agea (years) Location of exostoses Other clinical phenotypes Surgical therapy Pain
Family 1-II-1 M 19 Femur, tibia, fibula, ulna Forearm deformity No No
Family 2-II-1 M 23 Femur, tibia, fibula, ulna, radius Shortened ulna, negatively curved arm No No
Family 3- III-9 M 17 Femur, tibia, fibula, ulna, radius, clavicle Deformity of wrist joint, dislocation of
acromioclavicular joint
Yes No
Family 4-II-2 M 28 Femur, tibia, fibula, ulna, radius, ilium,
pubis
Forearm deformity, dislocation of
radioulnar joint
Yes No
Family 5-II-3 F 25 Femur, tibia, fibula No No No
Family 6-II-2 F 24 Femur, tibia, fibula, ulna No No No
Family 7-III-1 F 17 scapula, femur Absence of uterus No No
Family 8-III-1 M 14 Femur, tibia, fibula, ulna – No –
Family 9-III-2 M 10 Femur, tibia, fibula, ulna, radius,
humerus, scapula
No No No
Family 10-II-1 M 27 Radius, femur Chondrosarcoma Yes Yes
Family 11-II-2 M 40 Femur, tibia, ulna, radius No Yes No
Family 11-III-1 F 11 Femur, tibia, fibula, humerus, ulna,
radius, ilium, pubis, ischium, clavicle,
scapula, ribs, phalanx
Forearm deformity, dislocation of elbow
joint
Yes No
Family 11-III-2 F 9 scapula, clavicle, rib No No No
Family 12-II-1 M 26 Femur, tibia, ulna, radius, rib Knee joint dysfunction No No
Family 13-II-1 F 37 Femur, tibia, fibula No No No
Family 13-III-3 M 4 tibia, fibula, ulna, radius, humerus Scoliosis No No
Family 13-III-4 F 11 Femur, tibia, fibula No No No
Family 13-III-5 M 8 Femur, tibia, fibula, humerus, ulna,
radius, ilium, sternum, scapula, ribs
Scoliosis, thoracolumbar kyphosis,
Vertebral fusion, hemivertebra deformity
Yes No
Family 14-II-1 F 23 Femur, tibia, fibula, rib Chondrosarcoma Yes Yes
Family 15-III-1 M 13 Femur, tibia, fibula, humerus, ulna,
radius, ilium, pubis, vertebra
Knee joint dysfunction Yes No
Family 16-I-2 F 70 Femur Hip osteoarthritis, necrosis of femoral
head, and scoliosis
No Yes
Family 16-II-3 M 48 Humerus, tibia, ulna, and radius No No No
Family 16-II-5 M 45 Femur, fibula, and radius Dislocation of radioulnar joint No No
Family 16-II-8 F 40 Femur and humerus No No No
Family 16-III-1 M 26 Femur, tibia, fibula, humerus, ulna and
radius
Forearm deformity and wrist joint
dysfunction
No No
Family 16-III-5 M 13 Femur, tibia, fibula, ulna, and radius No No No
Family 16-III-9 F 7 Femur and rib No No No
Family 16-III-11 M 14 Femur, tibia, fibula, humerus, ulna, and
radius
No Yes No
Family 16-III-12 M 12 Femur, tibia, fibula, humerus, ulna, and
radius
No Yes No
Family 17- I -1 M 45 Femur and tibia No Yes No
Family 17-II-1 M 13 Femur, tibia, fibula, and phalanx No No No
Family 18-II-1 M 10 Femur, ulna, radius, and scapula No Yes No
Family 19-II-1 M 25 Femur, tibia, fibula No No No
Family 20-II-1 M 24 Humerus, femur, tibia No No No
Family 21-II-1 M 19 Femur, fibula, radius, ulna No No No
Family 22-II-1 M 22 Femur, tibia, fibula No No No
aAge at the time of diagnosis.
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FIGURE 2 | Special exostosis lesions and complications in some affected MO individuals. (A,B) Radiographs of Family 13 member III-5 as anteroposterior and
lateral views, revealing the scoliosis, thoracolumbar kyphosis and vertebral fusion (arrow). (C) Right forearm of Family 11 member III-1, showing exostosis in the ulna
and dislocation of the elbow joint (arrow). (D) Right forearm of Family 4 member II-2, showing exostosis in the ulna and bowed forearm conferring dislocation of
radioulnar joint (arrow). (E) Radiograph of Family 7 member III-1, revealing the exostoses in the scapula (arrow). (F) Radiograph of Family 4 member II-2, showing the
exostosis at the right side of the first rib (arrow). (G) Pelvic radiograph of Family 4 member II-2, displaying exostosis on the left side of the ilium (arrow).
(H) Ultrasound images of Family 7 member III-1, showing the absence of a uterus (arrow).





















TABLE 2 | EXT1 and EXT2 variants in the 22 Chinese families with multiple osteochondromas.
Family Gene Location Nucleotide
changea










1 EXT1 Exon 1 c.368_369delinsC p.Lys123Thrfs*13 Frame shift – Negative Sanger sequencing
2 EXT1 Exon 1 c.917delA p.Lys306Serfs*53 Frame shift Yes – Negative WES
3 EXT1 Exon 2 c.1019G > A p.Arg340His Missense 3.98e-6 Positive WES
4 EXT1 Exon 2 c.1019G > A p.Arg340His Missense 3.98e-6 Positive WES
5 EXT1 Exon 2 c.1049_1051delinsAATCTGATTCC p.Ala350Glufs*12 Frame shift Yes – Positive WES
6 EXT1 Exon 3 c.1065C > G p.Cys355Trp Missense Yes – Positive WES
7 EXT1 Intron 4 c.1284 + 1G > C – Splice site Yes – Positive WES
8 EXT1 Exon 9 c.1808_1836delinsTCCCAGTGGGATA p.Tyr603Ilefs*5 Frame shift Yes – Positive WES
9 EXT1 Exon 10 c.1942C > T p.Gln648* Non-sense – Positive Sanger sequencing
10 EXT1 Exon 10 c.2034T > G p.Tyr678* Non-sense – Positive Sanger sequencing
11 EXT1 Exons 2-8 g.118825104_119054767dupins
CCTTTTCTTTTTCCTTCCTTCC
Structural variant – Positive Sanger + MLPA
+WGS
12 EXT2 Exon 3 c.544C > T p.Arg182* Non-sense – Positive Sanger sequencing
13 EXT2 Exon 5 c.831_832delAG p.Glu278Valfs*7 Frame shift Yes 3.98e-6 Positive Sanger sequencing
14 EXT2 Intron 7 c.1173 + 2dupT – Splice site Yes – Negative WES
15 EXT2 Exon 8 c.1188G > A p.Trp396* Non-sense – Positive Sanger sequencing
16 EXT2 Whole gene g.43936139_44438043delins
GAGAAAAGCATTTGCAAA
AAGTATGA
– Structural variant – Positive Sanger + FISH
+ MLPA + WGS
17 EXT2 Whole gene g.43936139_44438043
delinsGAGAAAAGCATTTGCAA
AAAGTATGA
– Structural variant – Positive Sanger + MLPA
+ WGS
18 EXT2 Exons 2–8 g.44128440_44198500
delinsTCTTG
– Structural variant – Positive Sanger + MLPA
+ WGS
19 Undetected Positive WES + MLPA
20 Undetected Negative Sanger
sequencing + MLPA
21 Undetected Negative Sanger
sequencing + MLPA
22 Undetected Negative Sanger
sequencing + MLPA
aHGVS recommended nomenclature (www.hgvs.org/mutnomen/) was used to describe sequence variations. For the c. nomenclature, the A of the ATG translation initiation codon of the EXT1 (NM_000127) or EXT2
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FIGURE 3 | In silico analyses with respect to three novel variants. (A) Prediction of the potential effect of EXT1 c.1284 + 1G > C on splicing by Alamut. (B) Prediction
of the potential effect of EXT2 c.1173 + 2dupT on splicing by Alamut. (C) Structure model of EXT1. The N-terminal region (amino acid residues 29–461) is shown
here in cartoon form. Helix, sheet and loop are colored in red, yellow and green, respectively. The side chains of Cys355 and Cys334 are shown as spheres colored
in cyan.
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Pathogenic EXT1 and EXT2 Variants
Found in the Patients
The EXT1 and EXT2 variants detected in 18 of the 22 families (i.e.,
families 1–18) are summarized in Table 2 alongside the detection
methods employed. Of the 16 unique variants, the three large
duplication or deletion variants (namely, duplication of EXT1
exons 2–8, deletion of the entire EXT2 gene, and deletion of exons
2–8 of EXT2) have been previously described in Su et al. (2015)
and Wang et al. (2015). Of the remaining 13 variants, 6 were
already logged in HGMD and/or EXT1 and EXT2 locus-specific
mutation databases whereas 7 were not (as of 12 September
2020). The Sanger sequencing chromatograms for the seven
newly described variants (5 in EXT1 and 2 in EXT2) are shown
in Supplementary Figure S1. All 16 variants were either absent
or present at extremely low frequency (<0.00001) in the Genome
Aggregation Database (gnomAD)13 (Table 2). Additionally, in
families (excepting the mutation-negative Families 19–22) where
additional members were available for genetic analysis, the
respective variants were invariably found in patients but not in
healthy subjects (Figure 1).
Of the 16 unique variants, 12 appear to be loss of function
by virtue of their nature, irrespective of whether or not they
had been previously described; these included all frameshift
(n = 5) and non-sense (n = 4) variants and the gross duplication
and deletion (n = 3) variants. Of the two splice site variants
identified, EXT1 c.1284 + 1G > C was also highly likely to be of
pathological significance due to its disruption of the canonical 2-
bp GT splice donor site (Lin et al., 2019); the Alamut prediction
concurred with this assumption (Figure 3A). The pathogenic
relevance of the EXT2 c.1173 + 2dupT variant was not however
immediately apparent because it did not alter the canonical 2-bp
GT donor splice site. Alamut was therefore employed to predict
its impact on splicing. As shown in Figure 3B, all five in silico
algorithms provided by the Alamut suite under default conditions
predicted that the variant allele would exhibit significantly
reduced splicing potential as compared to the wild-type allele. We
further employed the recently developed SpliceAI (Jaganathan
et al., 2019) to predict the impact of the two splice-site variants
on splicing and, as previously described (Chen et al., 2020), we
focused our analysis exclusively on the Delta scores of donor
loss although other scores may provide clues as to the nature
of the resulting aberrantly spliced transcripts of splice-altering
variants. Both variants were predicted to have a high probability
of altering splicing, the Delta scores of donor loss being 0.91
and 0.99 for EXT1 c.1284 + 1G > C and EXT2 c.1173 + 2dupT,
respectively (Delta scores range from 0 to 1, with 1 indicating the
highest probability of altering splicing). As for the two missense
variants (both in EXT1), c.1019G > A (p.Arg340His) has been
reported in > 30 MO patients according to the EXT1 locus-
specific mutation database and was predicted by VarSome to be
pathogenic (verdict based on 11 pathogenic predictions from
BayesDel_addAF, DANN, DEOGEN2, EIGEN, FATHMM-MKL,
M-CAP, MVP, MutationAssessor, MutationTaster, PrimateAI and
REVEL vs. 1 benign prediction from SIFT).
13https://gnomad.broadinstitute.org/
The newly described EXT1 c.1065C > G (p.Cys355Trp)
was predicted by VarSome to be “likely pathogenic” (verdict
based on 10 pathogenic predictions from BayesDel_addAF,
DEOGEN2, FATHMM-MKL, M-CAP, MVP, MutationAssessor,
MutationTaster, PrimateAI, REVEL and SIFT vs. 2 benign
predictions from DANN and EIGEN). Most importantly,
two other missense variants that affected the p.Cys355 site,
p.Cys355Arg and p.Cys355Tyr, have previously been identified
in MO patients (Jennes et al., 2009; Ishimaru et al., 2016),
adding significant weight to our contention that p.Cys355Trp
is of pathological relevance. To provide further insight into
this question, we performed structural modeling of EXT1. The
N-terminal region of EXT1 belongs to the GT47 family, but
protein structure information from this domain is so far lacking.
We therefore used the latest TrRosetta method on Robetta server
(Hiranuma et al., 2020; Yang et al., 2020), a deep learning-
based method, to predict the structure of human EXT1. This
model shows that the N-terminal part of EXT1 comprises two
domains, which adopt a GT-B-like fold. The classical GT-B
fold is composed of two distinct N-terminal and C-terminal
Rossmann-like domains of six or seven parallel-sheet linked
FIGURE 4 | Distribution of the described EXT1 (A) and EXT2 (B) variants in
accordance with their respective gene/protein structures. The green boxes
denote the numbered exons. Novel mutations are shown in red. The
horizontal line indicates the approximate demarcations of the genomic
deletions in EXT2 (red) and duplication in EXT1 (blue). The protein domains of
EXT1 and EXT2 are presented at the bottom of each gene depiction, and
were derived from the Protein Families (Pfam) database.
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to α-helices, connected by a linker region and an interdomain
cleft. This model predicted that the Cys355 is located in the
center of the second lobe and can form a disulfide bond with
Cys334 (Figure 3C). Therefore, Cys355 probably plays a critical
role in stabilizing the protein; substitution of Cys by a larger
hydrophobic residue Trp (and other residues) would abolish
the disulfide bond, thereby impacting both the stability and
enzymatic activity of EXT1.
In short, pathogenic variants were found in 82% (n = 18) of
the 22 MO families, with EXT1 and EXT2 variants being detected
in 50% (11/22) and 32% (7/22) of cases, respectively. Figure 4
illustrates these variants in terms of their locations within their
respective gene/protein sequences.
Families 19–22 remained genetically unexplained after whole-
exome sequencing (WES) or Sanger sequencing followed by
MLPA (Table 2). Karyotyping was further performed on
probands of families 19, 20, and 21, showing no chromosome
abnormalities (Supplementary Figure S2). This served to rule
out the presence of chromosome rearrangements in excess of 5–
10 MB in the three cases. Finally, family 19-II-1 was analyzed by
WES, the resulting variants of unknown significance are provided
in Supplementary Table S1.
TABLE 3 | Summary of PGT-M/PGT-A results from three families.
Sample no. PGT cycle Biopsy time Embryo PGT-M result PGT-A result Outcome
Halpotype Sanger Sequencing
Family 4-II-3 1 Day 5 Embryo-1 Affected Heterozygote + 21
Day 5 Embryo-2 Normal Normal Euploid Transfer
Day 5 Embryo-3 Normal Normal −mos(18)(q12.1)
Day 5 Embryo-4 Affected Heterozygote Euploid
Day 5 Embryo-5 Affected Heterozygote −mos(6)(q21),-16
Day 5 Embryo-6 Normal Normal Euploid
Day 5 Embryo-7 Affected Heterozygote Euploid
Day 6 Embryo-8 Normal Normal Euploid
Day 6 Embryo-9 Affected Heterozygote Euploid
Day 6 Embryo-10 Normal Normal −13
Family 5-II-3 1 Day 5 Embryo-1 Normal Normal −22
Day 5 Embryo-2 Affected Heterozygote Euploid
Day 5 Embryo-3 Normal Normal + (6)(q14.3)
Day 5 Embryo-4 Affected Heterozygote Euploid
Day 5 Embryo-5 Affected Heterozygote + mos(15)
Day 6 Embryo-6 Normal Normal Multiple chromosome
abnormality
Day 6 Embryo-7 Maternal Affected
Haploidy
Hemizygote −8, + 22
2 Day 5 Embryo-1 Affected Heterozygote −15
Day 5 Embryo-2 Affected Heterozygote + 22
Day 5 Embryo-3 Normal Normal −21
Day 5 Embryo-4 Affected Heterozygote Euploid
Day 5 Embryo-5 Affected Heterozygote −mos(13)(33%)
Day 6 Embryo-6 Normal Normal Euploid Transfer
Day 6 Embryo-7 Normal Normal + 18
Family 13-II-5 1 Day 5 Embryo-1 Normal Normal Euploid Transfer
Day 5 Embryo-2 Affected Heterozygote Euploid
Day 6 Embryo-3 Affected Heterozygote Euploid
TABLE 4 | Summary of the results of prenatal diagnosis in five families.




Fetus Methods Result Outcome
Family 6-II-2 1 17 + 6 W Family 6-III-2 Sanger sequencing Normal Born healthy
Family 7-II-2 1 17 + 5 W Family 7-III-2 Sanger sequencing Normal Born healthy
Family 10-II-2 1 17 + 4 W Family 10-III-1 Sanger sequencing Heterozygote Labor induction
Family 11-II-3 1 18 + 2 W Family 11-III-4 MLPA + chromosome microarray analysis Normal Born healthy
Family 12-II-2 1 17 + 3 W Family 12-III-1 Sanger sequencing Heterozygote Labor induction
2 17 W Family 12-III-2 Sanger sequencing Normal Born healthy
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Preimplantation Genetic Testing and
Prenatal Diagnosis in 8 MO Families
As MO is an autosomal dominant skeletal disorder, the risk of
this disease appearing in the offspring of an affected individual
is expected to be approximately 50%. It is therefore extremely
important in such cases to be able to provide prenatal diagnosis
or PGT with a view to preventing the reoccurrence of MO in the
affected families. Of the 18 MO families in which a genetic cause
could be unequivocally established, eight sought assistance with
this issue (those who were born healthy through the PGT were
marked with #, and those who directly received prenatal diagnosis
as a fetus were marked with ∗ in Figure 1).
Specifically, three couples conceived through in vitro
fertilization after PGT, a technique whereby a 5-day-old embryo
is tested in a laboratory to determine if it carries a particular
disease-causing variant. The three couples (Family 4-II-3, Family
5-II-3, and Family 13-II-5) underwent a total of four PGT
cycles. Trophectoderm biopsy and PGT-M/PGT-A (PGT for
Monogenic defects/PGT for Aneuploidies) were performed on
the 27 blastocysts. Twelve (44.4%) of the 27 embryos were found
not to harbor any EXT mutations by PGT-M whereas 13 of
the 27 embryos were found to be euploid by means of PGT-A
(Table 3). Three embryos (Embryo-2 of Family 4-II-3, Embryo-6
of Family 5-II-3 and Embryo-1 of Family 13-II-5) found to be
both mutative-negative and euploid were used for transfer, all
resulting in healthy live births at full term. Moreover, two of
the three PGT babies were subjected to prenatal diagnosis, both
showing no EXT1/EXT2 mutations.
The other five couples (Family 6-II-2, Family 7-II-2, Family
10-II-2, Family 11-II-3, and Family 12-II-2) elected to undergo
prenatal diagnosis on the fetus after the mothers had conceived
naturally. Genomic DNA, prepared from amniotic fluid cells
taken by ultrasound-guided amniocentesis at about 17 weeks
of gestation, was used to investigate whether or not the fetus
carried the pathogenic variant. The results and outcomes of
prenatal diagnosis in the 5 families were summarized in Table 4.
Pathogenic mutations were detected in the fetuses in families
10 and 12, and in both cases the pregnant women elected
to terminate the pregnancies. Fortunately, no mutations were
detected during the second pregnancy of Family 12-II-2.
In summary, seven babies from the eight MO families that
underwent either PGT or prenatal diagnosis were born healthy
and no abnormalities were observed in follow-up studies.
DISCUSSION
In the present study, we describe the analysis of the pathogenetic
basis of multiple osteochondromas (MO) in 22 Chinese families.
Our findings concur with those published previously in terms
of the overall variant detection rate, a preponderance of EXT1
variants as compared to EXT2 variants, and the predominance
of truncating variants (Santos et al., 2018; Fusco et al., 2019).
Nonetheless, several points are worth noting. First, in addition
to the previously described large EXT1 duplication (Su et al.,
2015) and two large EXT2 deletions (Wang et al., 2015),
seven novel variants were identified, thereby expanding the
mutational spectrum of the EXT1 and EXT2 genes in MO.
Notably, we identified a novel missense variant, p.Cys355Trp,
in one family. The previous report of two other missense
variants affecting the same amino acid, together with our
newly modeled EXT1 structure, provide firm support for the
pathogenicity of p.Cys355Trp. Second, a higher frequency
(22.2%) of large deletion or duplication variants was detected
in our cohort than in other studies (e.g., 4–9% in White
et al., 2004; Signori et al., 2007; Jennes et al., 2008; Pedrini
et al., 2011; Delgado et al., 2014), although it should be
born in mind that our cohort was relatively small. Third,
the absence of a uterus was discovered in a female MO
patient in Family 7-III-1. To the best of our knowledge, this
is the first time that such a phenotype has been reported in
an MO patient. Whether this was due directly to the EXT1
c.1284 + 1G > C variant identified or to a defect in another
unrelated gene(s) is unclear.
Four families (Families 19, 20, 21, and 22) were variant-
negative after WES or Sanger sequencing followed by MLPA
(Table 2). Families 19, 20, and 21 were additionally analyzed
by karyotyping (Supplementary Figure S2). However, MLPA
and karyotyping could not readily detect cryptic balanced
rearrangements such as inversions potentially affecting the EXT1
and/or EXT2 genes; and WES and Sanger sequencing did not
target the vast intronic and regulatory regions of the EXT1
and EXT2 genes. Moreover, mosaic variants below the mutation
detection threshold may be responsible for the mutation-negative
probands in Families 20–22 (as well as for some mutation-
negative parents in genetically explained families, i.e., parents in
Families 1, 2, and 14). Alternatively, these families may be due
to variants in the as yet uncloned EXT3 gene (Le Merrer et al.,
1994). Finally, it should be noted that we have tried but failed to
perform whole genome sequencing on the probands of Families
19–22 and WES on the probands of Families 20–22 owing to the
poor quality and/or insufficient amount of DNA.
Prenatal diagnosis and PGT are the only ways to prevent
the reoccurrence of MO in affected families. In this regard,
prenatal diagnosis of MO has been previously described in the
literature but in each report, at most two cases were studied
(Zhao et al., 2009; Zhu et al., 2011; Tang et al., 2013; Bai
et al., 2020). Herein, we described the processes and outcomes
of prenatal diagnosis in seven families, including five families
who received prenatal diagnosis directly, and two families who
received prenatal diagnosis to validate PGT results. Our study
is thus the largest to date in terms of reported MO patients
who received prenatal diagnosis. Moreover, to the best of our
knowledge, this is the first time that PGT has been successfully
implemented in MO families.
In summary, we identified 16 unique pathogenic EXT1
and EXT2 variants (including seven novel ones) in 18 (82%)
of 22 Chinese MO families, which has expanded further the
mutational spectrum of MO-causing variants in the two genes.
The identification of causative variants allowed us to provide
genetic counseling to 8 MO patients in terms either of PGT
or prenatal diagnosis, thereby preventing the reoccurrence of
the disease in the respective affected families. This is the first
report of the successful implementation of PGT in affected MO
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families and also the largest study in terms of reported subjects
undergoing prenatal diagnosis.
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